Annidis Corp  

(Public, CVE:RHA)   Watch this stock  
Find more results for cve:rha
+0.0050 (10.00%)
Aug 4 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.05
52 week 0.01 - 0.35
Open 0.05
Vol / Avg. 12,000.00/31,688.00
Mkt cap 5.93M
P/E     -
Div/yield     -
EPS -0.07
Shares 107.88M
Beta -1.30
Inst. own     -
May 28, 2015
Q1 2015 Annidis Corp Earnings Release

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -240.07% -239.96%
Operating margin -181.04% -198.90%
EBITD margin - -186.52%
Return on average assets -257.73% -181.46%
Return on average equity - -
CDP Score - -


100 Maple Grove
+1-519-6721524 (Phone)
+1-519-6726950 (Fax)

Website links


Annidis Corporation is a Canada-based eye-care solutions company. The Company’s product aims to improve healthcare through eye-centric products and services that help eye care professionals screen, detect, diagnose, treat and manage ocular diseases. The Company partners with ocular science institutions including the University of Ottawa Eye Institute, The Ottawa Health Research Institute and the University of Montreal, School of Optometry. The Company’s RHA is an integrated system with two components: RHA Instrument and RHA Report. The RHA instrument is a multi-spectral imaging digital ophthalmoscope with an optical system that captures image data through the retinal and subretinal layers enabling eye care professionals use to distinguish between ocular structures. The RHA Report is a data analysis and reporting software package that processes and analyzes the RHA image data sets, creating a program for professional assessment and diagnosis of the patient’s ocular and general health.

Officers and directors

Gerald Slemko Chairman of the Board
Age: 61
Zeljko Ribaric President, Director
Michael Francis Crowley Interim Chief Executive Officer, Director
Brian Baker Chief Financial Officer
Michael Mueller Director
Ying Zhi Gu Independent Director
Chunhang Yu Independent Director
Jinsong Zhang Independent Director